Dr Deepwant Singh is a Consultant Rheumatologist and Physician trained from East of England Multi-professional Deanery under Cambridge rotation for Rheumatology. He is a practising Rheumatologist in UK and India. He is a Fellow of Royal College of Physicians Edinburgh (FRCP Edin.) and serves as an editorial board member for 15 international journals. He is EULAR certified for practising Rheumatology. With his Masters in Clinical Research he has an honorary visiting role at West Suffolk Hospital NHS Foundation trust assisting academic activities with Stroke and Rehabilitation team. He is a member of Emerging EUlar NETwork (EMEUNET) and has been an ambassador for Acute and General Medicine (AGM) conference for last 4 years. He has received various accolades including Patient Safety and Health Service Journal â€œHSJâ€ award and also lately recognised for his contribution to the Trust and patient care for â€œGo the extra mileâ€ award. He has been contributing to International Forum on Quality and Safety in Healthcare with innovative ideas for the last five consecutive years. He remains active for various clinical research Trials as a co-investigator. His research interests focus on early inflammatory arthritis and paediatric rheumatology.
Deepwant Singh(Research Area)
Dr Deepwant Singh's His research interests focus on inflammatory arthritis and paediatric rheumatology.
Edward P Cohen completed his medical studies at Washington University (St Louis). Postdoctoral studies were at the University of Chicago, the NIH and the
University of Colorado. He has been a member of the faculty of Rutgers University, the University of Chicago and, most recently, the University
of Illinois. Cohen has published more than 135 peer-reviewed papers, in the field of tumor immunology, numerous reviews and book chapters.
Currently, Cohen is the CEO of Immune Cell Therapy, Inc., a tumor vaccine company
Edward P Cohen(Research Area)
Edward P Cohen research interest is on Cellular Immunology, Immunity, cancer, cancer antigens.
Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Rehovot Israel and postdoctoral NIH, USA and UCLA School of Medicine. She is the director of Molecular Microbiology laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Beer Sheva, Israel. He has published more than 65 papers in reputed journals.
Yaffa Mizrachi Nebenzahl(Research Area)
Yaffa Mizrachi Nebenzahl research expertise is on Biochemical and molecular viral and bacterial biology, Cell biology, Viral and bacterial pathogenesis, Innate and adaptive immune response to pathogens
Dr Kushnir is an Integrative Immunologist and distinguished scientist. She is an international speaker and educator, leading clinical innovator who joins molecular biology knowledge with ancient Chinese medicine methods. Dr Kushnir published her work on neuroimmune mediators in the top scientific journals.
Nataliya M Kushnir(Research Area)
Dr Kushnir's research interest is based on Allergy, Immunology
Dr. Patnaik is an international leader in the field of prostate cancer research, and a Principal Investigator recipient of numerous awards in recognition for his recent work. These include the United States Department of Defense Prostate Cancer Research Program Physician-Researcher Award, Bristol-Myers Squibb/International ImmunoOncology Network Award, Cancer Research Foundation Young Investigator Award, American Cancer Society Research Grant and Phi Beta Psi Research Organization Award. Most notably, Dr. Patnaik and his research team recently won the prestigious Prostate Cancer Foundation Challenge Award, given to 8 teams internationally, chosen from a global competition of 100 applications from 67 cancer research centers in 14 countries.
Akash Patnaik(Research Area)
Dr. Patnaik research interest is on genitourinary cancers, including prostate, bladder, kidney and testicular cancer. Dr. Patnaik's work focuses on translating novel therapies from the laboratory to early stage clinical trials. He is interested in developing personalized patient models of disease in order to interpret therapeutics, develop biomarkers, and help patients make informed decisions about their care.
Harry W Schroeder Jr completed his MD PhD at the age of 28 years from Baylor College of Medicine. He then completed residency in Internal Medicine at the age of 31 at the University of Kentucky, fellowship in Medical Genetics at the University of Washington, postdoctoral studies at the Howard Hughes Medical Institute at the University of Washington, and a sabbatical year at the Institute for Genetics at the University of Cologne. He is the director of the Program in Immunology at the University of Alabama at Birmingham,. He has published more than 120 papers in reputed journals and has served as an editorial board member several journals of repute.
Harry W. Schroeder(Research Area)
Harry W. Schroeder research expertise is on B cell and repertoire development and Genetics of primary immune deficiency diseases.
Prof. Chak Thida, completed MD at the age of 27 years from the University of health Sciences (UoHS), Phnom Penh (P-P), Cambodia and postdoctoral studies to be a psychiatrist at the age 0f 40 from the UoHS, Phnom Penh and University Oslo, Norway, Director of psychiatric department of the UoHS, P-P and Vice director of Khmer Soviet Friendship Hospital, P-P. Prof. Chak Thida have been international published 2 papers and have been local study for more than 15 papers serving as an editorial board member of repute.
Chak Thida (Research Area)
Prof. Chak Thida research interest is on Psychological distress, HIV/AIDS and ARV
Professor Andrzej K. Siwicki, VMD, Ph.D., DSc is a head of Department Microbiology and Clinical Immunology, Faculty of Veterinary Medicine, University of Warmia and Mazury and Department of Pathology and Immunology IFI in Olsztyn, Poland. He is author of over 500 original papers in reputed journals and about 200 scientific communications (index-h 32, index of citation: 4502). His fields of interest are modulation of defence mechanisms and protection against diseases by natural and synthetic products in animals, influence of pollutants on the cell-mediated immunity and restoration of immunity after suppression induced by xenobiotics. Developed a new possibility in the comparative immunotoxicology for control of effect of xenobiotics and pharmaceutical products on the defence mechanisms and protection against diseases. He attended scientific missions in USA, Japan, France and Israel, was a co-ordinator of USDA and FAO projects and he is professor conferring of 14 PhDs and 4 DSc.
Andrzej K. Siwicki(Research Area)
Andrzej Siwicki research expertise is on microbiology and clinical immunology and assesses the impact of xenobiotics on the animal and human body. The scope of scientific activity includes: pathogenicity of selected groups of viruses and bacteria, Evaluation of the effects of chemotherapeutics and other xenobiotics on immunocompetent cells and cell and humoral immune responses, immunohomostasis immunoassay, modulation of cell and humoral immunity after xenobiotics-induced suppression, improvement of rapid diagnostic methods for viral and bacterial diseases using monoclonal antibody and cytometry techniques application of molecular biology in the diagnosis of infectious diseases and therapy, improvement of immunoprophylaxis methods: biostimulators, mono and polyvalent and recombinant vaccines and epidemiology associated with zoonoses.
Reinhard Pabst is the Professor of Institute for Immunomorphology, Centre of Anatomy Medical School Hannover, Germany. 2002 to 2006 he was Dean for Research at Medical School Hannover. He was Head of Institute of Functional and Applied Anatomy 1992 to 2009. From 2009 to 2015 he was Senior Research Prof. in Immunohistology.
Reinhard Pabst(Research Area)
Reinhard Pabst research expertise is on lymphocyte migration, bone marrow, Regeneration of auto transplanted fragments of lymph nodes.
Marcus Saemann is Head of the 6th Medical Department with Nephrology and Dialysis, Wilhelminenspital Vienna, Austria.
Previously, he was senior consultant nephrologist, at the Medical University of Vienna, Austria. He has more than 15 years of experience in all branches of nephrology including the whole spectrum of clinical nephrology, acute kidney injury, chronic kidney diseases, kidney transplantation, kidney-pancreas transplantation, intensive care nephrology, all extracorporal strategies such as hemodialysis, hemofiltration, peritoneal dialysis, along with plasmapheresis including immunoadsorption. Further clinical focus is the treatment of both type 1 and 2 diabetes mellitus especially with chronic kidney disease (diabetic kidney disease).
Marcus Saemann(Research Area)
Marcus Saemann research interest is on Diabetic kidney disease including Renin-Angiotensin-Aldosteron-System, HDL Cholesterol in Chronic Kidney Disease, Post-Transplant Diabetes mellitus,Diabetes management including insulin pump and continuous glucose measurement (CGM) technology (artificial pancreas, Immunosuppression after renal transplantation, especially mTOR inhibition, CMV infection, Urinary tract infection
Dr. Rongtuan Lin is Associate Professor - Department of Medicine, Division of Experimental Medicine. He has published more than 20 papers in differebt journals. he is involved in many projects such as Regulation of the interferon antiviral defense pathway, Small molecule agonists of the RIG-I pathway as innate stimulatory agents against virus infection, Combination oncolytic virotheapy for the treatment of prostate cancer.
Rongtuan Lin(Research Area)
Dr. Rongtuan Lin research interest is on Innate Immunity, Interferon Sginaling, Viral Evasion.
Dr. Kwon had his PhD from the Georgia Regents University, in 1981 and postdoctoral studies at the Department of Human Genetics, Yale University from 1981 to 1984. Dr. Kwon was a tenured Professor of the Indiana University School of Medicine, a Professor and Director of the Immunomodulation Research Center at the University of Ulsan, a Distinguished Professor and Investigator at the National Cancer Center, Korea, and Professor at the Department of Medicine Tulane University, New Orleans LA . He is currently the Founder and CEO of Eutilex who is developing T cell therapeutics and immunomodulatory antibody therapeutics. He has published over 300 peer-reviewed papers and has been serving as an editorial member of reputable journals.
Byoung S. Kwon(Research Area)
Byoung S. Kwon research expertise is focuses on immunotherapy against cancers and autoimmune diseases. Dr. Kwon has established a concept called â€œinducible costimulationâ€ by discovering 4-1BB-4-1BBL and AITR-AITRL systems. He has proved that immune functions can be selectively suppressed or enhanced through the inducible costimulation and presented the possibility of â€œselective immunotherapyâ€. Antigen-specific T cell therapeutics that Dr. Kwonâ€™s team has developed are in phase 1 trials against various cancers in the NCC.